Breast, ovarian and other site cancer patients with BRCA 1/2 mutations: Data from Turkish multicenter retrospective study

Basit Öğe Kaydı
dc.authorscopusid55987915300
dc.authorscopusid57193238894
dc.authorscopusid6504396778
dc.authorscopusid57217125486
dc.authorscopusid57194440555
dc.authorscopusid23059468500
dc.authorscopusid57204445210
dc.contributor.authorKöstek, O.
dc.contributor.authorKücükarda, Ahmet
dc.contributor.authorTozkır, Hilmi
dc.contributor.authorNihat Okten, I.
dc.contributor.authorÖzden, E.
dc.contributor.authorÇabuk, D.
dc.contributor.authorCicin, İrfan
dc.date.accessioned2022-05-11T14:41:14Z
dc.date.available2022-05-11T14:41:14Z
dc.date.issued2021
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Genetik Ana Bilim Dalı
dc.description.abstractPurpose: To demonstrate the clinical and demographic findings of the patients harboring BRCA1/2 mutations with breast, genital tract, prostate and pancreas cancers. Methods: The results of sequencing analysis of 200 cancer patients (190 women, 10 men) who had been directed to genetic counseling with an indication BRCA1/ BRCA2 testing from different regions across 9 medical oncology centers were retrospectively analyzed. Results: A total of 200 consecutive cancer patients who harbored BRCA1/BRCA2 mutation [130 (65%) patients harbored BRCA 1 mutation, and 70 harbored BRCA 2 mutation] were included. Of these, 64.0% had breast cancer, 31.5% had genital cancers, 3.5% had prostate and 1.0% had pancreatic cancers. The age at diagnosis [57 (IQR 50-66) years] of parents who had BRCA mutant cancer was higher than the age of their children who had BRCA mutant cancer [median age 45 (IQR 38-45) years]. BRCA2 carriers with ovarian cancer had favorable survival outcomes. In ovarian cancer patients, progression-free survival longer than 12 months was significantly more frequent in BRCA2 carriers compared with those in BRCA1 carriers. Conclusions: Newly diagnosed BRCA 1/2 carriers with cancers were younger than their parents who harbored BRCA mutation with cancer. The findings from Turkish BRCA 1/2 associated cancer patients suggest that earlier onset of the screening program and genetic counseling of BRCA associated patients and their family members are essential to earlier disease diagnosis and to prevent disease occurrence as well. © 2021 Zerbinis Publications. All rights reserved.
dc.identifier.endpage2661
dc.identifier.issn1107-0625
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85123535142
dc.identifier.scopusqualityQ3
dc.identifier.startpage2654
dc.identifier.urihttps://hdl.handle.net/20.500.11776/9114
dc.identifier.volume26
dc.indekslendigikaynakScopus
dc.institutionauthorTozkır, Hilmi
dc.language.isoen
dc.publisherZerbinis Publications
dc.relation.ispartofJournal of B.U.ON.
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBRCA1
dc.subjectBRCA2
dc.subjectBreast
dc.subjectGenital cancers
dc.subjectPancreas
dc.subjectPancreas
dc.subjectProstate
dc.titleBreast, ovarian and other site cancer patients with BRCA 1/2 mutations: Data from Turkish multicenter retrospective study
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu